Upgrade to SI Premium - Free Trial

Genmab A/S (GMAB)

39.57 +0.50 (1.28%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (11/5/26)

Latest Headlines

Morgan Stanley Assumes Genmab A/S (GMAB) at Equalweight October 20, 2026 3:15 AM - StreetInsider Genmab A/S (GEN:DC) (GMAB) PT Raised to DKK3,100 at UBS October 14, 2026 4:42 AM - StreetInsider Form 6-K GENMAB A/S For: Oct 13 October 13, 2026 7:50 AM - SEC Filing Darzalex Q3 2026 net sales reach $4.24 billion, reports Genmab October 13, 2026 6:24 AM - StreetInsider Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2026 October 13, 2026 6:22 AM - Globe NewsWire Form 6-K GENMAB A/S For: Oct 07 October 7, 2026 12:28 PM - SEC Filing Genmab A/S (GMAB) PT Raised to $58 at Guggenheim October 7, 2026 7:33 AM - StreetInsider Genmab A/S (GMAB) PT Raised to $45 at Truist Securities October 7, 2026 7:13 AM - StreetInsider Genmab A/S (GMAB) PT Raised to $50 at H.C. Wainwright October 7, 2026 6:51 AM - StreetInsider Form SCHEDULE 13G GENMAB A/S Filed by: Darwin Global Management, Ltd. October 5, 2026 9:30 PM - SEC Filing Genmab stock surges 11% on positive cancer drug trial data October 5, 2026 4:30 PM - StreetInsider Form 6-K GENMAB A/S For: Oct 05 October 5, 2026 3:28 PM - SEC Filing AbbVie and Genmab Announce Epcoritamab in Combination with R-CHOP Demonstrates Significant Improvement in Progression-Free Survival versus R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell October 5, 2026 2:55 PM - PR NewsWire Genmab and AbbVie drug cuts lymphoma progression risk by 51% October 5, 2026 2:53 PM - StreetInsider Genmab and AbbVie Announce Epcoritamab in Combination with R-CHOP Demonstrates Statistically Significant Improvement in Progression-Free Survival in Patients with Newly Diagnosed Diffuse Large B-Cell October 5, 2026 2:49 PM - StreetInsider Genmab A/S (GMAB) PT Raised to $54 at Guggenheim October 5, 2026 6:23 AM - StreetInsider Leerink Resumes Genmab A/S (GMAB) at Outperform October 5, 2026 6:19 AM - StreetInsider Genmab's Rina-S shows 45.9% response rate in ovarian cancer trial October 3, 2026 3:40 PM - StreetInsider Genmab Announces Rinatabart Sesutecan (Rina-S®) Phase 2 RAINFOL™-01 Results Demonstrated Durable and Clinically Meaningful Responses in Patients with Platinum-Resistant Ovarian Cancer October 3, 2026 3:40 PM - StreetInsider Form 6-K GENMAB A/S For: Oct 02 October 2, 2026 1:51 PM - SEC Filing Major Shareholder Announcement October 2, 2026 1:49 PM - Globe NewsWire Form 6-K GENMAB A/S For: Sep 29 September 29, 2026 10:40 AM - SEC Filing Form 6-K GENMAB A/S For: Sep 24 September 24, 2026 2:46 PM - SEC Filing Grant of Restricted Stock Units and Warrants to Employees in Genmab September 24, 2026 2:33 PM - StreetInsider H.C. Wainwright Reiterates Buy Rating on Genmab A/S (GMAB) September 14, 2026 7:33 AM - StreetInsider Capital Increase in Genmab as a Result of Employee Warrant Exercise September 8, 2026 2:44 PM - StreetInsider Notice to Convene an Extraordinary General Meeting of Genmab A/S September 8, 2026 6:00 AM - StreetInsider Genmab A/S (GEN:DC) (GMAB) PT Raised to DKK2,900 at Barclays September 8, 2026 5:38 AM - StreetInsider BofA Securities Reiterates Buy Rating on Genmab A/S (GEN:DC) (GMAB) September 4, 2026 6:06 AM - StreetInsider Genmab A/S (GEN:DC) (GMAB) PT Raised to DKK2,500 at Deutsche Bank September 1, 2026 4:44 AM - StreetInsider Form SCHEDULE 13G/A GENMAB A/S Filed by: ORBIS INVESTMENT MANAGEMENT LTD August 14, 2026 1:15 PM - SEC Filing Form 6-K GENMAB A/S For: Aug 12 August 12, 2026 9:49 AM - SEC Filing Form 6-K GENMAB A/S For: Aug 11 August 11, 2026 2:15 PM - SEC Filing Capital Increase in Genmab as a Result of Employee Warrant Exercise August 11, 2026 1:54 PM - StreetInsider Genmab A/S (GEN:DC) (GMAB) PT Raised to DKK2,700 at UBS August 7, 2026 4:37 AM - StreetInsider Genmab stock falls despite H1 revenue rise August 6, 2026 1:20 PM - StreetInsider Form 6-K GENMAB A/S For: Jun 30 August 6, 2026 11:09 AM - SEC Filing Genmab revenue rises 25% in first half of 2026, guidance raised August 6, 2026 11:02 AM - StreetInsider Genmab Announces Financial Results for the First Half of 2026 August 6, 2026 11:01 AM - Globe NewsWire Genmab and AbbVie say epcoritamab trial missed U.S. survival goal July 23, 2026 4:00 PM - StreetInsider Genmab and AbbVie Provide Clarification on Phase 3 EPCORE® DLBCL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) July 23, 2026 4:00 PM - StreetInsider Full Article List